SVA [SINOVAC BIOTECH] 6-K: (Original Filing)

[Sinovac Reports Unaudited First Quarter 2019 Financial Results BEIJING, China, July 10, 2019 /PRNewswire/ -- Sinovac Biotech Ltd. (NASDAQ: SVA) (“Sinovac” or the “Company”), a leading provider of biopharmaceutical products in China, announced today its unaudited financial results for the first quart]

By | 2019-07-12T03:31:27+00:00 July 11th, 2019|Categories: Chinese Stocks, SEC Original, SVA|Tags: , , , , , |0 Comments

SVA [SINOVAC BIOTECH] 6-K: Sinovac Reports Unaudited First Quarter 2019 Financial Results

[Sinovac Reports Unaudited First Quarter 2019 Financial Results BEIJING, China, July 10, 2019 /PRNewswire/ -- Sinovac Biotech Ltd. (NASDAQ: SVA) (“Sinovac” or the “Company”), a leading provider of biopharmaceutical products in China, announced today its unaudited financial results for the first quart]

By | 2019-07-12T03:31:31+00:00 July 11th, 2019|Categories: Chinese Stocks, SVA, Webplus ver|Tags: , , , , , |0 Comments

SVA [SINOVAC BIOTECH] 6-K: (Original Filing)

[Sinovac Reports Unaudited First Quarter 2019 Financial Results BEIJING, China, July 10, 2019 /PRNewswire/ -- Sinovac Biotech Ltd. (NASDAQ: SVA) (“Sinovac” or the “Company”), a leading provider of biopharmaceutical products in China, announced today its unaudited financial results for the first quart]

By | 2019-07-11T12:03:03+00:00 July 11th, 2019|Categories: Chinese Stocks, SEC Original, SVA|Tags: , , , , , |0 Comments

SVA [SINOVAC BIOTECH] 6-K: Sinovac Reports Unaudited First Quarter 2019 Financial Results

[Sinovac Reports Unaudited First Quarter 2019 Financial Results BEIJING, China, July 10, 2019 /PRNewswire/ -- Sinovac Biotech Ltd. (NASDAQ: SVA) (“Sinovac” or the “Company”), a leading provider of biopharmaceutical products in China, announced today its unaudited financial results for the first quart]

By | 2019-07-11T12:03:09+00:00 July 11th, 2019|Categories: Chinese Stocks, SVA, Webplus ver|Tags: , , , , , |0 Comments

SVA [SINOVAC BIOTECH] 6-K: (Original Filing)

[Sinovac Reports Unaudited Second Half of 2018 Financial Results and Files 2018 Annual Report on Form 20-F Second Half of 2018 Financial Highlights Ÿ Sales for the second half of 2018 were $107.2 million, which remains the same compared to $107.4 million in the prior year period. Revenue generated by]

By | 2019-05-01T03:44:11+00:00 April 30th, 2019|Categories: Chinese Stocks, SEC Original, SVA|Tags: , , , , , |0 Comments

SVA [SINOVAC BIOTECH] 6-K: Sinovac Reports Unaudited Second Half of 2018 Financial

[Sinovac Reports Unaudited Second Half of 2018 Financial Results and Files 2018 Annual Report on Form 20-F Second Half of 2018 Financial Highlights Ÿ Sales for the second half of 2018 were $107.2 million, which remains the same compared to $107.4 million in the prior year period. Revenue generated by]

By | 2019-05-01T03:44:18+00:00 April 30th, 2019|Categories: Chinese Stocks, SVA, Webplus ver|Tags: , , , , , |0 Comments

SVA [SINOVAC BIOTECH] 20-F: (Original Filing)

[None None (Title of Class) Indicate the number of outstanding shares of each of the issuer’s classes of capital or common stock as of the close of the period covered by the annual report. 71,139,402 common shares as of December 31, 2018 ☐ Yes ☒ No ☐ Yes ☒ No ☒ Yes ☐ No ☒ Yes ☐ No ☐ Large] [Contract ]

By | 2019-04-30T04:15:56+00:00 April 29th, 2019|Categories: Chinese Stocks, SEC Original, SVA|Tags: , , , , , |0 Comments

SVA [SINOVAC BIOTECH] 20-F: None None (Title of Class) Indicate the number

[None None (Title of Class) Indicate the number of outstanding shares of each of the issuer’s classes of capital or common stock as of the close of the period covered by the annual report. 71,139,402 common shares as of December 31, 2018 ☐ Yes ☒ No ☐ Yes ☒ No ☒ Yes ☐ No ☒ Yes ☐ No ☐ Large] [Contract ]

By | 2019-04-30T04:16:00+00:00 April 29th, 2019|Categories: Chinese Stocks, SVA, Webplus ver|Tags: , , , , , |0 Comments

SVA [SINOVAC BIOTECH] 6-K: (Original Filing)

[Sinovac Announces Positive Results From Phase III Trial Of a Sabin Strain-Based Inactivated Polio Vaccine (sIPV) Published in the Journal of Infectious Disease · The Sinovac-developed sIPV demonstrates both long-term affordability and accessibility and has the potential to contribute significantly t]

By | 2019-04-17T03:40:08+00:00 April 16th, 2019|Categories: Chinese Stocks, SEC Original, SVA|Tags: , , , , , |0 Comments

SVA [SINOVAC BIOTECH] 6-K: Sinovac Announces Positive Results From Phase III Trial

[Sinovac Announces Positive Results From Phase III Trial Of a Sabin Strain-Based Inactivated Polio Vaccine (sIPV) Published in the Journal of Infectious Disease · The Sinovac-developed sIPV demonstrates both long-term affordability and accessibility and has the potential to contribute significantly t]

By | 2019-04-17T03:40:14+00:00 April 16th, 2019|Categories: Chinese Stocks, SVA, Webplus ver|Tags: , , , , , |0 Comments
Skip to toolbar